Concepts (56)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antimitotic Agents | 1 | 2016 | 8 | 0.580 |
Why?
|
| Oligopeptides | 1 | 2016 | 429 | 0.470 |
Why?
|
| Bone Neoplasms | 1 | 2016 | 2576 | 0.230 |
Why?
|
| Cell Proliferation | 1 | 2016 | 7226 | 0.230 |
Why?
|
| Prostatic Neoplasms | 2 | 2017 | 5767 | 0.220 |
Why?
|
| Durapatite | 1 | 2016 | 31 | 0.140 |
Why?
|
| Ions | 1 | 2016 | 53 | 0.140 |
Why?
|
| Tubulin Modulators | 1 | 2016 | 65 | 0.140 |
Why?
|
| Tibia | 1 | 2016 | 131 | 0.130 |
Why?
|
| Th17 Cells | 1 | 2017 | 162 | 0.130 |
Why?
|
| Phosphates | 1 | 2016 | 187 | 0.130 |
Why?
|
| Interleukin-17 | 1 | 2017 | 250 | 0.130 |
Why?
|
| Microtubules | 1 | 2016 | 270 | 0.130 |
Why?
|
| Thiazoles | 1 | 2017 | 726 | 0.110 |
Why?
|
| Cell Cycle | 1 | 2016 | 2084 | 0.090 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2023 | 2027 | 0.090 |
Why?
|
| Tumor Burden | 1 | 2016 | 1987 | 0.090 |
Why?
|
| Esophageal Neoplasms | 1 | 2023 | 3168 | 0.090 |
Why?
|
| Cell Survival | 1 | 2016 | 3045 | 0.090 |
Why?
|
| Calcium | 1 | 2016 | 1537 | 0.090 |
Why?
|
| Neoplasm Invasiveness | 1 | 2017 | 3981 | 0.080 |
Why?
|
| Menopause | 1 | 2008 | 159 | 0.080 |
Why?
|
| Sulfonamides | 1 | 2017 | 1823 | 0.080 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2016 | 3821 | 0.080 |
Why?
|
| Women's Health | 1 | 2008 | 205 | 0.070 |
Why?
|
| Inflammation | 1 | 2017 | 2522 | 0.070 |
Why?
|
| Disease Models, Animal | 2 | 2017 | 7222 | 0.070 |
Why?
|
| Congresses as Topic | 1 | 2008 | 298 | 0.070 |
Why?
|
| Publishing | 1 | 2008 | 220 | 0.070 |
Why?
|
| Liver Neoplasms | 1 | 2023 | 4557 | 0.070 |
Why?
|
| Cell Line, Tumor | 2 | 2023 | 14551 | 0.070 |
Why?
|
| Antibodies, Monoclonal | 1 | 2017 | 4367 | 0.060 |
Why?
|
| Glypicans | 1 | 2023 | 51 | 0.060 |
Why?
|
| Kynurenine | 1 | 2023 | 71 | 0.050 |
Why?
|
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2023 | 69 | 0.050 |
Why?
|
| Mice | 3 | 2023 | 34495 | 0.050 |
Why?
|
| Apoptosis | 1 | 2016 | 7591 | 0.050 |
Why?
|
| Animals | 3 | 2023 | 59536 | 0.040 |
Why?
|
| Injections, Intraperitoneal | 1 | 2017 | 197 | 0.040 |
Why?
|
| B7-H1 Antigen | 1 | 2023 | 1022 | 0.030 |
Why?
|
| Drug Monitoring | 1 | 2017 | 333 | 0.030 |
Why?
|
| Neoplastic Stem Cells | 1 | 2023 | 1443 | 0.030 |
Why?
|
| Immunologic Factors | 1 | 2017 | 649 | 0.030 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2023 | 3251 | 0.030 |
Why?
|
| Prostate | 1 | 2017 | 1088 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2023 | 3869 | 0.020 |
Why?
|
| Quality of Life | 1 | 2023 | 4532 | 0.020 |
Why?
|
| Male | 2 | 2017 | 123000 | 0.020 |
Why?
|
| Humans | 4 | 2023 | 261506 | 0.020 |
Why?
|
| Molecular Targeted Therapy | 1 | 2017 | 2330 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2008 | 1085 | 0.010 |
Why?
|
| Societies, Medical | 1 | 2008 | 1335 | 0.010 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2008 | 1303 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2017 | 32848 | 0.010 |
Why?
|
| United States | 1 | 2008 | 15433 | 0.010 |
Why?
|
| Female | 1 | 2008 | 141928 | 0.000 |
Why?
|